Revolution Medicines counsel sells 2,157 shares

Revolution Medicines, Inc. General Counsel Jeff Cislini reported an open-market sale of 2,157 shares of common stock at a weighted average price of $156.1191 per share.

Rhea-AI Filing Summary

Revolution Medicines, Inc. General Counsel Jeff Cislini reported an open-market sale of 2,157 shares of common stock at a weighted average price of $156.1191 per share. The trade was executed under a Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. After this transaction, he holds 56,521 shares, including 43,514 restricted stock units and 160 shares acquired through the company’s Employee Stock Purchase Plan.

Insider Trade Summary 10b5-1

Net Seller: 2,157 shares

Net Sell 1 txn

Insider Cislini Jeff

Role General Counsel

Sold 2,157 shs ($337K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,157	$156.1191	$337K

Holdings After Transaction: Common Stock — 56,521 shares (Direct)

Footnotes (4)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. F2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8251. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. F3. Includes 43,514 RSUs.
4. F4. Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

Key Figures

Shares sold: 2,157 shares Sale price: $156.1191 per share Holdings after sale: 56,521 shares +4 more

7 metrics

Shares sold 2,157 shares Open-market sale of common stock

Sale price $156.1191 per share Weighted average sale price

Holdings after sale 56,521 shares Total common stock held following transaction

RSUs included in holdings 43,514 RSUs Restricted stock units included in post-transaction holdings

ESPP shares included 160 shares Shares acquired under Employee Stock Purchase Plan on May 31, 2026

10b5-1 plan adoption date May 31, 2023 Rule 10b5-1 instruction letter adoption

Transaction date June 16, 2026 Date of open-market sale

Key Terms

Rule 10b5-1, restricted stock units ("RSUs"), weighted average price, Employee Stock Purchase Plan, +1 more

5 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock units ("RSUs") financial

"to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs")"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

weighted average price financial

"The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Employee Stock Purchase Plan financial

"Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RVMD General Counsel Jeff Cislini report in this Form 4 filing?

Jeff Cislini reported selling 2,157 shares of Revolution Medicines common stock in an open-market transaction. The reported weighted average sale price was $156.1191 per share, with the trade disclosed as part of his routine SEC reporting obligations.

Was the RVMD insider stock sale by Jeff Cislini pre-planned under Rule 10b5-1?

Yes. The sale was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023. Such plans pre-arrange trades, helping insiders systematically sell shares without timing decisions based on nonpublic information.

Why did RVMD’s General Counsel sell 2,157 shares of common stock?

The filing states the transaction was made to satisfy tax withholding obligations from vesting restricted stock units. This means shares were sold primarily to cover taxes due when RSUs converted into taxable income.

How many RVMD shares does Jeff Cislini hold after this transaction?

After the sale, Jeff Cislini holds 56,521 shares of Revolution Medicines common stock. This figure includes 43,514 restricted stock units and 160 shares acquired through the company’s Employee Stock Purchase Plan.

At what price were the RVMD shares sold in this insider transaction?

The reported weighted average price for the 2,157 sold shares was $156.1191 per share. The filing notes the trade was executed in multiple lots with prices ranging from $156.1105 to $156.8251.

What does it mean that RVMD shares were sold in multiple trades with a weighted average price?

The sale was broken into several trades at prices between $156.1105 and $156.8251. The weighted average price of $156.1191 reflects the share-count-weighted mean, simplifying disclosure while detailed trade data remains available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		S(1)		2,157	D	$156.1191(2)	56,521(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. This transaction was executed in multiple trades at prices ranging from $156.1105 to $156.8251. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. Includes 43,514 RSUs.

4. Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)